Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes Mellitus: A 3-Year Post-Marketing Surveillance Study

被引：0
|
作者：
Fumiko Yamamoto
Yuriko Unno
Tomoo Okamura
Rie Ikeda
Kaori Ochiai
Naoyuki Hayashi
机构：
[1] Nippon Boehringer Ingelheim Co.,Medicine Division
[2] Ltd.,PMS Division
[3] EPS Corporation,undefined
来源：
Diabetes Therapy | 2020年 / 11卷
关键词：
DPP-4 inhibitor; Japanese; Linagliptin; Long-term; Post-marketing surveillance; Type 2 diabetes mellitus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：107 / 117
页数：10
相关论文
共 50 条
  • [11] Safety and effectiveness of ipragliflozin in Japanese patients with type 2 diabetes mellitus and impaired renal function: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM)
    Tobe, Kazuyuki
    Maegawa, Hiroshi
    Nakamura, Ichiro
    Uno, Satoshi
    DIABETOLOGY INTERNATIONAL, 2021, 12 (02) : 181 - 196
  • [12] SAFETY AND EFFECTIVENESS OF IPRAGLIFLOZIN IN JAPANESE PATIENTS WITH TYPE 2 DIABETES MELLITUS AND IMPAIRED RENAL FUNCTION: SUBGROUP ANALYSIS OF A 3-YEAR POST-MARKETING SURVEILLANCE STUDY (STELLA-LONG TERM)
    Tobe, K.
    Maegawa, H.
    Nakamura, I
    Uno, S.
    DIABETES MELLITUS, 2021, 24 (02): : 141 - 155
  • [13] Long-Term Safety and Effectiveness of Thyrotropin Alfa in Japanese Patients: A Post-Marketing Surveillance Study
    Rie Kanamori
    Shiho Yamane
    Takeshi Seto
    Advances in Therapy, 2021, 38 : 4949 - 4960
  • [14] Long-Term Safety and Effectiveness of Thyrotropin Alfa in Japanese Patients: A Post-Marketing Surveillance Study
    Kanamori, Rie
    Yamane, Shiho
    Seto, Takeshi
    ADVANCES IN THERAPY, 2021, 38 (09) : 4949 - 4960
  • [15] Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan
    Kadowaki, Takashi
    Haneda, Masakazu
    Ito, Hiroshi
    Sasaki, Kazuyo
    Yamada, Yuka
    ADVANCES IN THERAPY, 2020, 37 (05) : 2477 - 2492
  • [16] Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan
    Takashi Kadowaki
    Masakazu Haneda
    Hiroshi Ito
    Kazuyo Sasaki
    Yuka Yamada
    Advances in Therapy, 2020, 37 : 2477 - 2492
  • [17] Cardiovascular safety and effectiveness of vildagliptin in patients with type 2 diabetes mellitus: a 3-year, large-scale post-marketing surveillance in Japan
    Ishida, Yosuke
    Murayama, Hiroki
    Shinfuku, Yohei
    Taniguchi, Tomoko
    Sasajima, Takayoshi
    Oyama, Naotsugu
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (05) : 625 - 631
  • [18] Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM)
    Tobe, Kazuyuki
    Maegawa, Hiroshi
    Nakamura, Ichiro
    Uno, Satoshi
    ENDOCRINE JOURNAL, 2021, 68 (08) : 905 - 918
  • [19] Safety and effectiveness of empagliflozin according to body mass index in Japanese patients with type 2 diabetes: a subgroup analysis of a 3-year post-marketing surveillance study
    Kaku, Kohei
    Yamamoto, Kazuhiro
    Fukushima, Yumiko
    Mizuno, Seiko
    Nitta, Daisuke
    EXPERT OPINION ON DRUG SAFETY, 2022, 21 (11) : 1411 - 1422
  • [20] Real-World Evidence for Long-Term Safety and Effectiveness of Ipragliflozin in Japanese Patients with Type 2 Diabetes Mellitus: final Results of a 3-Year Post-Marketing Surveillance Study (STELLA-LONG TERM) (vol 22, pg 373, 2020)
    Ichiro, Nakamura
    Hiroshi, Maegawa
    Kazuyuki, Tobe
    Satoshi, Uno
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (10) : I - I
12345